ReviewPLOS global public health2023
Advancing oncology drug therapies for sub-Saharan Africa.
Review in PLOS global public health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- ONMORE-Africa: diagnosing and building real-world oncology studies in Morocco and Africa.ESMO real world data and digital oncology · 2026Review
- Evaluating the current neuro-oncology capacity in Sub-Saharan Africa: A questionnaire-based survey.Neuro-oncology practice · 2026Article
- Cancer navigation in Africa: challenges, impacts, and future directions.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Review
- Cost of chemotherapy-related care for breast cancer care: evidence and implications from a provider perspective at a public tertiary hospital in South Africa.Health economics review · 2026Article
- Prediction of checkpoint inhibitor immunotherapy efficacy for cancer using routine blood tests and clinical data.Nature medicine · 2025Article
- Mapping Behavioral Research in Post-Treatment Cancer Care in Sub-Saharan Africa: A Scoping Review.Psycho-oncology · 2025Article
- Challenges and opportunities to address the emerging burden of targeted therapies in ovarian cancer.Gynecologic oncology reports · 2025Review
- Treatment approaches for prostate cancer in sub-Saharan Africa.Translational cancer research · 2024Review
- Screening and Testing for Homologous Recombination Repair Deficiency (HRD) in Breast Cancer: an Overview of the Current Global Landscape.Current oncology reports · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer incidence is rising across sub-Saharan Africa (SSA), and is often characterized by late-stage presentation, early age of onset and poor survival. While a number of oncology drugs are now improving the length and quality of life for cancer patients in high-income countries, significant disparities in access to a range of oncology therapeutics exist for SSA. A number of challenges to drug access such as drug costs, lack of infrastructure and trained personnel must be urgently addressed to advance oncology therapies for SSA. We present a review of selected oncology drug therapies that are likely to benefit cancer patients with a focus on common malignancies in SSA. We collate available data from seminal clinical trials in high-income countries to highlight the potential for these therapeutics to improve cancer outcomes. In addition, we discuss the need to ensure access to drugs within the WHO Model List of Essential Medicines and highlight therapeutics that require consideration. Available and active oncology clinical trials in the region is tabulated, demonstrating the significant gaps in access to oncology drug trials across much of the region. We issue an urgent call to action to address drug access due to the predicted rise in cancer burden in the region in coming years.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.